Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND)

Lishomwa C. Ndhlovu, Tracie Umaki, Glen M. Chew, Dominic C. Chow, Melissa Agsalda, Kalpana J. Kallianpur, Robert Paul, Guangxiang Zhang, Erika Ho, Nancy Hanks, Beau Nakamoto, Bruce T. Shiramizu, Cecilia M. Shikuma

Research output: Contribution to journalArticlepeer-review

72 Scopus citations

Fingerprint

Dive into the research topics of 'Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND)'. Together they form a unique fingerprint.

Medicine & Life Sciences